VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call
The Company will issue its second quarter 2025 earnings release on Thursday, August 7, 2025 after the close of trading on the New York Stock Exchange and host a conference call to discuss its financial and operational results on Friday morning, August 8, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time and 3:00 p.m. London Time.)
Interested parties in the United States may participate toll-free by dialing (833) 685-0907. Interested parties in the United Kingdom may participate toll-free by dialing 08082389064. Other international parties may dial (412) 317-5741. Participants should ask to be joined to the 'Vaalco Energy Earnings Conference Call.' This call will also be webcast on VAALCO's website at www.vaalco.com. An audio replay will be available on the Company's website following the call.
About Vaalco
Vaalco, founded in 1985 and incorporated under the laws of Delaware, is a Houston, Texas, USA based, independent energy company with a diverse portfolio of production, development and exploration assets across Gabon, Egypt, Côte d'Ivoire, Equatorial Guinea, Nigeria and Canada.
For Further Information
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
16 minutes ago
- National Post
WELL Health to Announce Second Quarter 2025 Financial Results on August 14, 2025
Article content VANCOUVER, British Columbia — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Second Quarter 2025 financial results for the period ended June 30, 2025, before the market opens on Thursday, August 14, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). The call will be hosted by Hamed Shahbazi, Chairman and Chief Executive Officer and Eva Fong, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call. Article content Conference Call Participant Details Article content Date: Thursday, August 14, 2025 Article content Time: 1:00 PM ET / 10:00 AM PT Article content International Toll: 289-514-5100 Article content North American Toll Free: 1-800-717-1738 Article content To attend the webcast, register now or visit for details. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Corp. Article content About WELL Health Technologies Corp. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Article content Article content Article content Contacts Article content Article content Article content Article content
National Post
16 minutes ago
- National Post
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
Article content Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa ® technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research Article content BILLERICA, Mass. — Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The announcement comes alongside Quanterix's robust presence at the Alzheimer's Association International Conference (AAIC) 2025, with more than 55 posters and presentations featuring data generated using its Simoa ® technology. Article content These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease. Developed on Quanterix's ultra-sensitive Simoa ® platform, our p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers. Article content Quanterix's growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa ® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside. Article content 'The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's,' said Masoud Toloue, PhD, CEO of Quanterix. 'Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we're advancing the future of precision diagnostics across neurology, oncology, and immunology.' Article content The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia. Article content To learn more about the new assays or Quanterix's expanded capabilities, visit or stop by the Quanterix booth at AAIC 2025. Article content About Quanterix Article content Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at Article content Article content Article content Article content Contacts Article content Media Contact: Marissa Klaassen (781) 913.8036 media@ Article content
CTV News
16 minutes ago
- CTV News
U.S. LNG producers soar as EU agrees to $250 billion in annual purchases
Shares of U.S. liquefied natural gas developers surged in premarket trading on Monday, after the European Union pledged to purchase US$750 billion worth of the super-cooled fuel over the next three years as part of a sweeping trade pact. NextDecade, Venture Global, and Cheniere Energy jumped between seven per cent and 8.8 per ent, with the deal bolstering the prospects for American LNG exporters as they expand to meet growing demand for cleaner-burning fuels. The EU, seeking to phase out its dependence on Russian gas, committed to buying $250 billion annually in U.S. LNG as part of the framework trade agreement unveiled on Sunday. The U.S. became the world's biggest LNG supplier in 2023, surpassing Australia and Qatar, as surging global prices fed demand for more exports, due in part to supply disruptions and sanctions linked to Russia's 2022 invasion of Ukraine. The agreement imposes a 15 per cent U.S. import tariff on most EU goods, a softer blow than markets had feared. 'Terms of the EU-U.S. trade deal were at the forefront, with the 15 per cent tariff level better than feared (30 per cent was mooted previously),' said Ashley Kelty, an analyst at Panmure Liberum. 'This should see less of a drag on industrial activity between the two.' Still, Kelty noted the deal could weigh on gas prices. 'The demand for the EU to buy more U.S. energy will see more U.S. LNG imports in the future,' Kelty said, signaling a potential supply glut. Shares of U.S. natural gas producers Expand Energy and EQT Corp were up 1.6 per cent and three per cent, respectively, before the bell. (Reporting by Arunima Kumar in Bengaluru; Editing by Sriraj Kalluvila)
